Literature DB >> 36100791

A Novel Porcine Model of CLN2 Batten Disease that Recapitulates Patient Phenotypes.

Vicki J Swier1, Katherine A White1, Tyler B Johnson1, Jessica C Sieren2,3, Hans J Johnson4, Kevin Knoernschild2,3, Xiaojun Wang5, Frank A Rohret5, Christopher S Rogers5, David A Pearce1,6, Jon J Brudvig1,6, Jill M Weimer7,8.   

Abstract

CLN2 Batten disease is a lysosomal disorder in which pathogenic variants in CLN2 lead to reduced activity in the enzyme tripeptidyl peptidase 1. The disease typically manifests around 2 to 4 years of age with developmental delay, ataxia, seizures, inability to speak and walk, and fatality between 6 and 12 years of age. Multiple Cln2 mouse models exist to better understand the etiology of the disease; however, these models are unable to adequately recapitulate the disease due to differences in anatomy and physiology, limiting their utility for therapeutic testing. Here, we describe a new CLN2R208X/R208X porcine model of CLN2 disease. We present comprehensive characterization showing behavioral, pathological, and visual phenotypes that recapitulate those seen in CLN2 patients. CLN2R208X/R208X miniswine present with gait abnormalities at 6 months of age, ERG waveform declines at 6-9 months, vision loss at 11 months, cognitive declines at 12 months, seizures by 15 months, and early death at 18 months due to failure to thrive. CLN2R208X/R208X miniswine also showed classic storage material accumulation and glial activation in the brain at 6 months, and cortical atrophy at 12 months. Thus, the CLN2R208X/R208X miniswine model is a valuable resource for biomarker discovery and therapeutic development in CLN2 disease.
© 2022. The American Society for Experimental Neurotherapeutics, Inc.

Entities:  

Keywords:  CLN2 Batten disease; Cortical atrophy; Electroretinogram a- and b-waves; Gait; Miniswine; Seizures

Year:  2022        PMID: 36100791     DOI: 10.1007/s13311-022-01296-7

Source DB:  PubMed          Journal:  Neurotherapeutics        ISSN: 1878-7479            Impact factor:   6.088


  61 in total

Review 1.  Neuronal ceroid lipofuscinoses: classification and diagnosis.

Authors:  K E Wisniewski; E Kida; A A Golabek; W Kaczmarski; F Connell; N Zhong
Journal:  Adv Genet       Date:  2001       Impact factor: 1.944

2.  A mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I activity and progressive neurodegeneration.

Authors:  David E Sleat; Jennifer A Wiseman; Mukarram El-Banna; Kwi-Hye Kim; Qinwen Mao; Sandy Price; Shannon L Macauley; Richard L Sidman; Michael M Shen; Qi Zhao; Marco A Passini; Beverly L Davidson; Gregory R Stewart; Peter Lobel
Journal:  J Neurosci       Date:  2004-10-13       Impact factor: 6.167

Review 3.  Current state of clinical and morphological features in human NCL.

Authors:  Hans H Goebel; Krystyna E Wisniewski
Journal:  Brain Pathol       Date:  2004-01       Impact factor: 6.508

4.  Synergistic effects of treating the spinal cord and brain in CLN1 disease.

Authors:  Charles Shyng; Hemanth R Nelvagal; Joshua T Dearborn; Jaana Tyynelä; Robert E Schmidt; Mark S Sands; Jonathan D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2017-07-03       Impact factor: 11.205

Review 5.  Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses.

Authors:  Maria Kousi; Anna-Elina Lehesjoki; Sara E Mole
Journal:  Hum Mutat       Date:  2011-11-16       Impact factor: 4.700

6.  Retinal pathology in a canine model of late infantile neuronal ceroid lipofuscinosis.

Authors:  Martin L Katz; Joan R Coates; Jocelyn J Cooper; Dennis P O'Brien; Manbok Jeong; Kristina Narfström
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-03-14       Impact factor: 4.925

7.  Enzyme replacement therapy attenuates disease progression in a canine model of late-infantile neuronal ceroid lipofuscinosis (CLN2 disease).

Authors:  Martin L Katz; Joan R Coates; Christine M Sibigtroth; Jacob D Taylor; Melissa Carpentier; Whitney M Young; Fred A Wininger; Derek Kennedy; Brian R Vuillemenot; Charles A O'Neill
Journal:  J Neurosci Res       Date:  2014-06-17       Impact factor: 4.164

8.  A tailored mouse model of CLN2 disease: A nonsense mutant for testing personalized therapies.

Authors:  Ryan D Geraets; Logan M Langin; Jacob T Cain; Camille M Parker; Rosanna Beraldi; Attila D Kovacs; Jill M Weimer; David A Pearce
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.752

9.  Mild respiratory SARS-CoV-2 infection can cause multi-lineage cellular dysregulation and myelin loss in the brain.

Authors:  Anthony Fernández-Castañeda; Peiwen Lu; Anna C Geraghty; Eric Song; Myoung-Hwa Lee; Jamie Wood; Belgin Yalçın; Kathryn R Taylor; Selena Dutton; Lehi Acosta-Alvarez; Lijun Ni; Daniel Contreras-Esquivel; Jeff R Gehlhausen; Jon Klein; Carolina Lucas; Tianyang Mao; Julio Silva; Mario A Peña-Hernández; Alexandra Tabachnikova; Takehiro Takahashi; Laura Tabacof; Jenna Tosto-Mancuso; Erica Breyman; Amy Kontorovich; Dayna McCarthy; Martha Quezado; Marco Hefti; Daniel Perl; Rebecca Folkerth; David Putrino; Avi Nath; Akiko Iwasaki; Michelle Monje
Journal:  bioRxiv       Date:  2022-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.